| Nov 13 |
Harrow Announces Third Quarter 2024 Financial Results
|
| Nov 13 |
Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
|
| Nov 13 |
Earnings Scheduled For November 13, 2024
|
| Nov 12 |
Harrow Health 2024 Earnings Preview
|
| Nov 12 |
Harrow Announces Market Access Wins for VEVYE®
|
| Nov 11 |
Harrow: VEVYE And Its Impact On The DED Market
|
| Nov 7 |
Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
|
| Oct 31 |
Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
|
| Oct 18 |
3 US Growth Stocks With High Insider Ownership And 167% Earnings Growth
|
| Oct 10 |
Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
|
